A complete understanding of therapy resistance requires functional interrogation of the biological ecosystem using interdisciplinary science.

Welcome, and thanks for visiting our website!

Our team is dedicated to unmasking the mechanisms that drive response and resistance to conventional and immuno-modulatory drugs for multiple diseases including cancer and neuro-psychiatry. Importantly, we also seek to provide immediate solutions in the clinic.

Our research lies at the forefront of innovation, integrating a unique interdisciplinary tool set including biology, mathematics, next-generation sequencing and bioengineering approaches. We also place a special emphasis on building an academic, integrated atmosphere culturing our future generation of successful scientists.

RECENT NEWS

August, 2024: Strategic Partnership and Sponsorship with Pluristyx Inc.

Aaron Goldman Builds Bridges to Advance Drug Development

March, 2023: New research article

Drug Resistance to benzodiazepines can be overcome with a new class of small molecules discovered by AstraZeneca in collaboration with the Goldman DRG

December, 2021: New research article

The Goldman DRG engineers blood-brain-barrier penetrating drugs that boost NK cell therapy for glioblastoma.

July, 2021: Funding

Cannex Scientific signs agreement with the Goldman Lab to study the therapeutic effect of cannabinoids and terpenes for multiple disease indications including neuro-psychiatry, gastroesophageal disease and lung injury

RESEARCH HIGHLIGHTS

RESISTANCE AND GAME THEORY

The behavior of cancer in the human body, and the impact it has on other normal and immune cells, can be explained by numerous phenomena. One way our team studies cancer’s behavior is through mathematical frameworks like game theory. We were featured on the cover of PLoS Computational Biology after elucidating novel behavior among cancer clones that drives resistance

RESISTANCE AND METABOLISM

Cell metabolism can affect the growth of cancer as well as it’s likelihood of developing drug resistance. Importantly, cell metabolism in immune cells can influence tumor immunogenicity. The Goldman DRG explores multiple aspects of metabolism in the tumor ecosystem. A recent article in Science Signaling we describe a novel metabolic phenotype that cancer cells induce while under drug pressure

CELL THERAPY RESPONSE AND RESISTANCE

Cell therapies are emerging as powerful tools in our anticancer arsenal. The Goldman DRG deploys interdisciplinary science including bioengineering and nanotechnology to design novel drugs that boost the activity of cell therapies in aggressive cancers. In two recent articles in Cancer Research and Front. Mol. Bio. we describe ways to overcome deficits of NK cell adoptive therapy by modulating tumor antigen expression and inactivating environmental factors

Proudly collaborating with:

A complete understanding of therapy resistance requires functional interrogation of the biological ecosystem using interdisciplinary science.